<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03224754</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0075</org_study_id>
    <nct_id>NCT03224754</nct_id>
  </id_info>
  <brief_title>Atypia of Undetermined Significance (AUS) / Follicular Lesion of Undetermined Significance (FLUS)</brief_title>
  <official_title>Understanding Management and Clinical Follow-up of Atypia of Undetermined Significance / Follicular Lesion of Undetermined Significance Category in Thyroid Fine Needle Aspiration: A 6 Year-retrospective Study in a Tertiary Care Center.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Mississippi Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the guidelines for reporting thyroid fine needle aspirations known as The
      Bethesda System, the category of atypical cells known as AUS/ FLUS category has an estimated
      rate of 5 to 15% for malignancy. This study aims to determine the rate of malignancy of this
      category in our institution and to evaluate the clinical outcome of the participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective study that will help us to find out the rate of AUS/ FLUS in our
      population of Mississippi and the percentage of malignancies in these cases.The specimens
      will be searched through the University of Mississippi Medical Center's Pathology Laboratory
      Information system (Copath), from April 2010 to December 2016. The retrospective cases will
      be retrieved using natural language search. The total number of thyroid FNA will be retrieved
      and the percentage of cases with AUS/ FLUS will be calculated. Followup of these cases will
      be done looking for additional fine needle aspirations of the thyroid or thyroidectomy
      specimens. Cases with diagnosis of AUS/ FLUS will have correlation with the diagnosis on the
      thyroidectomy specimens if available in our system.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants enrolled
  </why_stopped>
  <start_date type="Actual">July 18, 2017</start_date>
  <completion_date type="Actual">May 2, 2018</completion_date>
  <primary_completion_date type="Actual">May 2, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>6 Years</target_duration>
  <primary_outcome>
    <measure>Number of malignant cases in a subsequent thyroidectomy after a diagnosis of AUS/ FLUS</measure>
    <time_frame>From April 1st/ 2010 to December 31st 2016</time_frame>
    <description>All the cytology cases with a diagnosis of AUS/FLUS on fine needle aspiration from April 1st 2010 to December 31st 2016 will be retrieved using the University Medical Center's pathology information system (Copath). Follow-up of these cases will be done looking for percentage of malignancy in these cases.</description>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Diagnoses Disease</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Determination of risk of malignancy of these thyroid lesions</intervention_name>
    <description>This is a retrospective study that will help us to find out the rate of AUS/ FLUS in our population of Mississippi and the percentage of malignancies in these cases.The specimens will be searched through the University of Mississippi Medical Center's Pathology Laboratory Information system (Copath), from April 2010 to December 2016. The retrospective cases will be retrieved using natural language search. The total number of thyroid FNA will be retrieved and the percentage of cases with AUS/ FLUS will be calculated. Followup of these cases will be done looking for additional fine needle aspirations of the thyroid or thyroidectomy specimens. Cases with diagnosis of AUS/ FLUS will have correlation with the diagnosis on the thyroidectomy specimens if available in our system.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient that has a diagnosis of atypia of undetermined significance/ follicular lesion
        of undetermined significance after thyroid fine needle aspiration regardless the age, sex
        or any other condition.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Thyroid fine needle aspirations interpreted as AUS/ FLUS at University of Mississippi
             Medical Center from April 2010 to December 2016.

        Exclusion Criteria:

          -  Fine needle aspirations of thyroid with diagnosis of unsatisfactory, benign,
             suspicious for follicular neoplasm/ Follicular neoplasm, suspicious for malignancy and
             malignant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria F Gonzalez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mississippi Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Jo VY, Stelow EB, Dustin SM, Hanley KZ. Malignancy risk for fine-needle aspiration of thyroid lesions according to the Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol. 2010 Sep;134(3):450-6. doi: 10.1309/AJCP5N4MTHPAFXFB.</citation>
    <PMID>20716802</PMID>
  </results_reference>
  <results_reference>
    <citation>Baloch ZW, Cibas ES, Clark DP, Layfield LJ, Ljung BM, Pitman MB, Abati A. The National Cancer Institute Thyroid fine needle aspiration state of the science conference: a summation. Cytojournal. 2008 Apr 7;5:6. doi: 10.1186/1742-6413-5-6.</citation>
    <PMID>18394201</PMID>
  </results_reference>
  <results_reference>
    <citation>Ali SZ, Cibas ES. The Bethesda System for Reporting Thyroid Cytopathology. New York, NY: Springer; 2010</citation>
  </results_reference>
  <results_reference>
    <citation>Marchevsky AM, Walts AE, Bose S, Gupta R, Fan X, Frishberg D, Scharre K, Zhai J. Evidence-based evaluation of the risks of malignancy predicted by thyroid fine-needle aspiration biopsies. Diagn Cytopathol. 2010 Apr;38(4):252-9. doi: 10.1002/dc.21185.</citation>
    <PMID>19813257</PMID>
  </results_reference>
  <results_reference>
    <citation>Renshaw A. An estimate of risk of malignancy for a benign diagnosis in thyroid fine-needle aspirates. Cancer Cytopathol. 2010 Aug 25;118(4):190-5. doi: 10.1002/cncy.20092. Erratum in: Cancer Cytopathol. 2010 Oct 25;118(5):303.</citation>
    <PMID>20586117</PMID>
  </results_reference>
  <results_reference>
    <citation>Ho AS, Sarti EE, Jain KS, Wang H, Nixon IJ, Shaha AR, Shah JP, Kraus DH, Ghossein R, Fish SA, Wong RJ, Lin O, Morris LG. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS). Thyroid. 2014 May;24(5):832-9. doi: 10.1089/thy.2013.0317. Epub 2014 Mar 10.</citation>
    <PMID>24341462</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim TH, Jeong DJ, Hahn SY, Shin JH, Oh YL, Ki CS, Kim JW, Jang JY, Cho YY, Chung JH, Kim SW. Triage of patients with AUS/FLUS on thyroid cytopathology: effectiveness of the multimodal diagnostic techniques. Cancer Med. 2016 May;5(5):769-77. doi: 10.1002/cam4.636. Epub 2016 Jan 18.</citation>
    <PMID>26775803</PMID>
  </results_reference>
  <results_reference>
    <citation>Singh RS, Wang HH. Eliminating the &quot;Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance&quot; category from the Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol. 2011 Dec;136(6):896-902. doi: 10.1309/AJCPIX52MBOKTICP.</citation>
    <PMID>22095375</PMID>
  </results_reference>
  <results_reference>
    <citation>Yoo MR, Gweon HM, Park AY, Cho KE, Kim JA, Youk JH, Son EJ. Repeat Diagnoses of Bethesda Category III Thyroid Nodules: What To Do Next? PLoS One. 2015 Jun 26;10(6):e0130138. doi: 10.1371/journal.pone.0130138. eCollection 2015.</citation>
    <PMID>26115096</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Mississippi Medical Center</investigator_affiliation>
    <investigator_full_name>Maria F. Gonzalez</investigator_full_name>
    <investigator_title>Assisstant Professor of the department of Pathology</investigator_title>
  </responsible_party>
  <keyword>Atypia, thyroid, malignancy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

